Search
BridgeBio Pharma Inc
BBIOAdd to Watchlist
74.290USD
+0.020+0.03%
Close 11-06 16:00（ET）
14.47BMarket Cap
LossP/E TTM
Today
+0.03%
5 Days
-0.88%
1 Month
+10.95%
6 Months
+9.11%
Year to Date
-2.88%
1 Year
+18.43%
Key Figures
74.210Open
75.700High
158.10KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.08%Turnover Ratio
74.270Prev. Close
73.190Low
11.77MTurnover
LossP/E Static
-5.75P/B
0.00%Div Yield TTM
-64.80%ROA
93.41552wk High
0.04Volume Ratio
-535.76MNet Profit
194.80MShares
-3.7466EPS TTM
0.99Beta
--ROE
62.06052wk Low
7.16%Amplitude
94.26%Gross Margin
14.47BMarket Cap
-0.38Reward/Risk
2.80%Risk Rate
Recent
Transcripts
AstraZeneca PLC Stock (AZN) Moved Down by 6.72% on Jul 9: A Full Analysis
• AstraZeneca shares fell after the Wainua drug failed a late-stage clinical trial. • The CARDIO-TTRansform trial did not meet its primary cardiovascular mortality reduction objectives. • High usage of competitor medication likely masked the drug's therapeutic efficacy in patients.
TradingKeyThu, Jul 9
Merck & Co Inc Stock (MRK) Moved Down by 3.19% on Jun 1: A Full Analysis
• Merck shares declined despite positive oncology data. • Large acquisition charges may impact investor sentiment. • Analyst ratings are mostly "Buy" with a positive price target.
TradingKeyMon, Jun 1
BridgeBio Pharma Inc's Score
-0.11vs previous score
Forecast8.17
Financial Health7.43
Technical4.50
Valuation Dimensions9.33
Institutional Confidence10.00
Risk Assessment7.77
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
BridgeBio Pharma Inc Technical Analysis
Technical Indicators
Sell
Summary
Neutral
Moving Average
Buy
BridgeBio Pharma Inc Latest Earnings Call Transcripts
BridgeBio Pharma (BBIO) Q3 2026 Earnings Call: Attruby Revenue Up 134%, Three Launches Ahead
BridgeBio Pharma’s Q3 2026 revenue reached $353.2 million as Attruby sales rose 134%, while three priority-review FDA decisions approach.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.42/-0.58
Revenue / Forecast
353.17M/288.05M
BridgeBio Pharma Inc Profile
SectorPharmaceuticals
Ticker SymbolBBIO
Number of employees725
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 6.77% |
| BlackRock Institutional Trust Company, N.A. | 6.16% |
| Viking Global Investors LP | 6.05% |
| Janus Henderson Investors | 5.62% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 36.99% |
| Investment Advisor/Hedge Fund | 35.07% |
| Hedge Fund | 13.21% |
| Private Equity | 8.58% |
Related Instruments
-0.79%
+1.43%
+1.07%
-0.14%
+0.38%
-0.22%
+0.03%
-0.41%
+0.02%
-0.20%
+0.85%
-1.57%
-1.04%
+0.28%
+5.27%
-0.16%
+0.16%
-0.80%
+1.46%
+3.63%Popular Instruments
51290.600
-208.500 (-0.41%)
26964.500
+329.300 (+1.24%)
7380.000
+23.100 (+0.31%)
12797.000
-1.000 (-0.01%)
58142.000
+876.000 (+1.53%)
6140.600
-37.200 (-0.60%)
89.857
-0.176 (-0.20%)
342.370
-1.800 (-0.52%)
186.640
+5.040 (+2.78%)
4065.670
-33.020 (-0.81%)
FAQs
What is the current price of BridgeBio Pharma Inc (BBIO)?
The current price of BridgeBio Pharma Inc (BBIO) is 74.29.
What is the symbol of BridgeBio Pharma Inc?
The ticker symbol of BridgeBio Pharma Inc is BBIO.
What is the 52-week high of BridgeBio Pharma Inc?
The 52-week high of BridgeBio Pharma Inc is 93.42.
What is the 52-week low of BridgeBio Pharma Inc?
The 52-week low of BridgeBio Pharma Inc is 60.55.
What is the market capitalization of BridgeBio Pharma Inc?
The market capitalization of BridgeBio Pharma Inc is 14.47B.
Is BridgeBio Pharma Inc (BBIO) currently rated as Buy, Hold, or Sell?
According to analysts, BridgeBio Pharma Inc (BBIO) has an overall rating of Buy, with a price target of 106.58.
What is the Earnings Per Share (EPS TTM) of BridgeBio Pharma Inc (BBIO)?
The Earnings Per Share (EPS TTM) of BridgeBio Pharma Inc (BBIO) is -3.75.